Natalizumab Completed Phase 3 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00306592Natalizumab Re-Initiation of Dosing
NCT00030966Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
NCT00027300Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis